TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Alcidion Group Limited ( (AU:ALC) ).
Alcidion Group Limited reported a transformative financial year in FY25, achieving a record underlying EBITDA of $5.1 million and a 10% increase in revenue to $40.8 million. The company secured significant new contracts, including a major Electronic Patient Record deployment with North Cumbria NHS Trust, validating its dual market position. With a strong cash balance and no debt, Alcidion is poised for further growth in FY26, leveraging its Miya platform to expand into new markets and enhance patient flow solutions.
The most recent analyst rating on (AU:ALC) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
More about Alcidion Group Limited
Alcidion Group Limited operates in the healthcare technology industry, providing enterprise health technology solutions. Their primary product, Miya Precision, addresses significant healthcare challenges such as reducing emergency presentations, streamlining patient flow, and accelerating patient discharge. The company focuses on markets in the UK and Australia, offering modular and comprehensive platform solutions.
Average Trading Volume: 1,304,886
Technical Sentiment Signal: Buy
Current Market Cap: A$134.3M
For a thorough assessment of ALC stock, go to TipRanks’ Stock Analysis page.